Drug Approval | December 26, 2024
Aarti Drugs receives EIR from USFDA for Tarapur API facility
This facility is considered to be in a minimally acceptable state of compliance with regard to current GMP
This facility is considered to be in a minimally acceptable state of compliance with regard to current GMP
Despite NTC014, due to its simplified therapeutic regimen, has been administered at a lower posology than the antibiotic comparator
Bringing a new drug to market takes about 10 years and requires an investment of approximately $1 billion
The new facility significantly increases Siegfried’s R&D capacity to drive development excellence and further growth
Jagsonpal Pharmaceuticals has received full consideration of Rs. 41 crore towards the sale of the facility and will now be proceeding with registration formalities
For Q2, Akums reported a consolidated total income of Rs. 1,046.6 crore
The company uses iPS cells to develop treatments for diseases relating to the kidney
This is in pursuance to the announcement made in the Union Budget for the year 2024-25 exempting these three anti-cancer medicines from customs duty
Aarti Drugs has reported total income of Rs. 599.81 crores during the period ended September 30, 2024
Akums Drugs will undertake this development and commercialization in India
Subscribe To Our Newsletter & Stay Updated
